CLINICAL PHARMACOLOGY and THERAPEUTICS

Editor

Walter Modell, M.D.

Editorial Board

Arthur J. Atkinson, Jr., M.D.
Frank M. Berger, M.D., D.Sc.
Karl H. Beyer, Jr., M.D., Ph.D.
Hylan A. Bickerman, M.D.
Edward A. Carr, Jr., M.D.
Leighton E. Cluff, M.D.
Allan H. Conney, Ph.D.
T. S. Danowski, M.D.
Arthur C. DeGraff, M.D.
Peter Dineen, M.D.
Edward F. Domino, M.D.
Alvan R. Feinstein, M.D.
Max Fink, M.D.
Robert B. Forney, Ph.D.
Emil Frei, III, M.D.
Franz Gross, M.D.
Arthur Hull Hayes, Jr., M.D.
Leo E. Hollister, M.D.
Bartholomew P. Hsi, Ph.D.
Murray E. Jarvik, M.D.
Ernest Jawetz, M.D., Ph.D.
Stanley A. Kaplan, Ph.D.
Attallah Kappas, M.D.
Arthur S. Keats, M.D.
Richard H. Kessler, M.D.
Joseph B. Kirsner, M.D., Ph.D.
Kenneth G. Kohlstaedt, M.D.
Louis Lasagna, M.D.
Louis Lemberger, M.D., Ph.D.
Gerhard Levy, Pharm.D.
T. A. Loomis, M.D., Ph.D.
Daniel S. Lukas, M.D.
Fletcher H. McDowell, M.D.
Dean T. Mason, M.D.
Jerry R. Mitchell, M.D., Ph.D.
Arno G. Motulsky, M.D.
R. K. Richards, M.D.
David G. Shand, M.B., Ph.D.
Jay Tepperman, M.D.
Leroy D. Vandam, M.D.
Elliot S. Vesell, M.D.
John G. Wagner, Ph.D.
E. Leong Way, Ph.D.

Volume 21, January-June, 1977
The C. V. Mosby Company, St. Louis

Volume 21
Copyright © 1977 by
The C. V. Mosby Company

All rights reserved

Printed in the United States of America

Index to volume 21

Author index

A

AKAMATSU, T. J. (*See* Wong et al.), 709
ALDOUS, S., AND THOMAS, R. Absorption and metabolism of lanatoside C. II. Fate after oral administration, 647
ALLEN, J. P. (*See* Ludden et al.), 287
ALLEN, M. D. (*See* Greenblatt et al.), 355, 497 (Special article)
AMERY, A., DE PLAEN, J.-F., LIJNEN, P., MCAINSH, J., AND REYBROUCK, T. Relationship between blood level of atenolol and pharmacologic effect, 691
AMLIE, J. (*See* Storstein and Amlie), 255, 659
ANDRES, R. (*See* Vestal et al.), 343
ANTONIN, K. H. (*See* Klotz and Antonin), 736
—. (*See* Klotz et al.), 430
ARRUDA, J. A. L. (*See* Lang et al.), 234
ÅSBERG, M., RINGBERGER, V.-A., SJÖQVIST, F., THORÉN, P., TRÄSKMAN, L., AND TUCK, J. R. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine, 201
ASBURY, M. (*See* Ramsay et al.), 602
ATKINSON, A. J., JR., LEE, W.-K., QUINN, M. L., KUSHNER, W., NEVIN, M. J., AND STRONG, J. M. Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions, 575

B

BACHUR, N. R., RIGGS, C. E., JR., GREEN, M. R., LANGONE, J. J., VAN VUNAKIS, H., AND LEVINE, L. Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay, 70
BARDEN, T. P. (*See* Bloomfield et al.), 414
BARTLETT, M. F. (*See* Luders et al.), 721
BATY, J. D., AND ROBINSON, P. R. Acetaminophen production in man after coadministration of acetanilid and phenacetin, 177
BENOWITZ, N. L., AND JONES, R. T. Prolonged delta - 9 - tetrahydrocannabinol ingestion, 336
BEN-ZVI, Z. (*See* Danon et al.), 643
BIECK, P. R. (*See* Klotz et al.), 430
BIGGS, J. T. (*See* Petit et al.), 47
BLASCHKE, T. F. (*See* Williams et al.), 301
BLOOMFIELD, S. S., BARDEN, T. P., AND MITCHELL, J. Naproxen, aspirin, and codeine in postpartum uterine pain, 414
BREIMER, D. D., ZILLY, W., AND RICHTER, E. Influence of rifampicin on drug metabolism: Differences between hexobarbital and antipyrine, 470
BROWN, H. C. (*See* McDevitt et al.), 556
BRÜGEL, H. (*See* Klotz et al.), 430
BRUNZELL, J. D. (*See* Goldberg et al.), 317
BURROWS, G. D. (*See* Norman et al.), 453

C

CALIMLIM, J. F., WARDELL, W. M., DAVIS, H. T., LASAGNA, L., AND GILLIES, A. J. Analgesic efficacy of an orally administered combination of pentazocine and aspirin, 34
CALVEY, T. N., AND CHAN, K. Plasma pyridostigmine levels in patients with myasthenia gravis, 187
CARRUTHERS, S. G. (*See* McDevitt et al.), 556
CHABRIA, N. L. (*See* Kulkarni et al.), 685
CHADHA, D. R. (*See* Kulkarni et al.), 685
CHAN, K. (*See* Calvey and Chan), 187
CIPOLLE, R. J. (*See* Sawchuk et al.), 362
COLLINS, R. L. (*See* Davis et al.), 52
COMER, W. H. (*See* Greenblatt et al.), 222
CONNEY, A. H. (*See* Kapitulnik et al.), 158, 166
CONVERY, R. F. (*See* Wong et al.), 709
COOKE, E. C. (*See* Kumar et al.), 520
CORDER, M. P., SHEETS, R. F., STONE, W. H., FLANNERY, E. P., JUSTICE, G. R., AND HERBST, K. D. Leucovorin in combination chemotherapy of breast cancer, 464
CRAMMER, J. (*See* Nikitopoulou et al.), 422
CUMMINGS, W. B. (*See* Scott et al.), 208

D

DAHL, S. G., AND STRANDJORD, R. E. Pharmacokinetics of chlorpromazine after single and chronic dosage, 437
DANON, A., HOROWITZ, J., BEN-ZVI, Z., KAPLANSKI, J., AND GLICK, S. An outbreak of digoxin intoxication, 643
DANSETTE, P. M. (*See* Kapitulnik et al.), 158
DASILVA, L. M. (*See* Kulkarni et al.), 685
DAVIES, B. (*See* Norman et al.), 453

January, pp. 1-124; February, pp. 125-246; March, pp. 247-374; April, pp. 375-514; May, pp. 515-642; June, pp. 643-768.

DAVIES, D. S., WING, L. M. H., REID, J. L., NEILL, E., TIPPETT, P., AND DOLLERY, C. T. Pharmacokinetics and concentration-effect relationships of intravenous and oral clonidine, 593
DAVIS, H. T. (*See* Calimlim et al.), 34
DAVIS, J. D., TURNER, R. A., COLLINS, R. L., RUCHTE, I. R., AND KAUFMANN, J. S. Fenoprofen, aspirin, and gold induction in rheumatoid arthritis, 52
DAYTON, P. G. (*See* Pruitt et al.), 610
DE LA VEGA, C. E., SLATER, S., ZIEGLER, M. G., LAKE, C. R., AND MURPHY, D. L. Reduction in plasma norepinephrine during fenfluramine treatment, 216
DE PLAEN, J.-F. (*See* Amery et al.), 691
DE ZEEUW, R. A. (*See* Jonkman et al.), 457
DHUPELIA, V. B. (*See* Lang et al.), 234
DIGIORE, C. (*See* Schrogie et al.), 1
DITZLER, C. A. (*See* Duggan et al.), 326
DOLLERY, C. T. (*See* Davies et al.), 593
—. (*See* Kersting et al.), 547
DUARTE, J. E. (*See* Malcolm et al.), 567
DUGGAN, D. E., HARE, L. E., DITZLER, C. A., LEI, B. W., AND KWAN, K. C. The disposition of sulindac, 326

E

EGGER, H. (*See* Luders et al.), 721

F

FALLEN, E. L. (*See* Sniderman et al.), 267
FEINSTEIN, A. R. Clinical biostatistics
XXXVIII. Computer malpractice, 78
XXXIX. The haze of Bayes, the aerial palaces of decision analysis, and the computerized Ouija board, 482
FERGUSON, R. K., TUREK, D. M., AND RONER, D. R. Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension, 62
FITZGERALD, J. D. (*See* Sutton et al.), 700
FLANNERY, E. P. (*See* Corder et al.), 464
FRANKEL, H. L. (*See* Reid et al.), 375
FRISK-HOLMBERG, M., JORFELDT, L., AND JUHLIN-DANNFELDT, A. Influence of alprenolol on hemodynamic and metabolic responses to prolonged exercise in subjects with hypertension, 675
FUCHS, J. C. A. (*See* Malcolm et al.), 567

G

GAITO, M. J. (*See* Luders et al.), 721
GARLE, M. (*See* Hoppel et al.), 294
GERBER, N. (*See* Olsen et al.), 147
GHIA, J. (*See* Raft et al.), 26
GIFFORD, R. W., JR. A message from the President, American Society for Clinical Pharmacology and Therapeutics, 245
GILFRICH, H.-J. (*See* Meinertz et al.), 731
GILLIES, A. J. (*See* Calimlim et al.), 34
GLICK, S. (*See* Danon et al.), 643
GOLDBERG, A. P., SHERRARD, D. J., HAAS, L. B., AND BRUNZELL, J. D. Control of clofibrate toxicity in uremic hypertriglyceridemia, 317
GREEN, M. R. (*See* Bachur et al.), 70
GREENBLATT, D. J., ALLEN, M. D., NOEL, B. J., AND SHADER, R. I. Acute overdosage with benzodiazepine derivatives, 497 (Special article)
—, —, AND SHADER, R. I. Toxicity of high-dose flurazepam in the elderly, 355
—., JOYCE, T. H., COMER, W. H., KNOWLES, J. A., SHADER, R. I., KYRIAKOPOULOS, A. A., MACLAUGHLIN, D. S., AND RUELIUS, H. W. Clinical pharmacokinetics of lorazepam. II. Intramuscular injection, 222
GREGG, J. (*See* Raft et al.), 26
GROSBERG, S. J. (*See* Thompson et al.), 392
GROTH, U. (*See* Meinertz et al.), 731
GUM, O. B. (*See* Luders et al.), 721

H

HAANEN, C. (*See* van Prooijen et al.), 744
HAAS, L. B. (*See* Goldberg et al.), 317
HARE, L. E. (*See* Duggan et al.), 326
HARRIS, L. (*See* Raft et al.), 26
HARRIS, S. (*See* Schrogie et al.), 1
HARRISON, I. (*See* Ramsay et al.), 602
HASSAR, M., POCELINKO, R., WEINTRAUB, M., NELSON, D., THOMAS, G., AND LASAGNA, L. Free-living volunteer's motivations and attitudes toward pharmacologic studies in man, 515
HENDERSON, G. L., WILSON, B. K., AND LAU, D. H. M. Plasma *l*-α-acetylmethadol (LAAM) after acute and chronic administration, 16
HENSLEY, M. J. (*See* Schrogie et al.), 1
HEPNER, G. W., AND VESELL, E. S. Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease, 620
HERBST, K. D. (*See* Corder et al.), 464
HOEHN, M. M. (*See* Katz and Hoehn), 388
HOFFMAN, S. F. (*See* Ludden et al.), 287
HOPPEL, C., GARLE, M., RANE, A., AND SJÖQVIST, F. Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients, 294
HOROWITZ, J. (*See* Danon et al.), 643
HUGHSON, R. L. (*See* Sutton et al.), 700

I

INABA, T. (*See* Kalow et al.), 530

J

JÄHNCHEN, E. (*See* Meinertz et al.), 731
JAIN, A. K., RYAN, J. R., VARGAS, R., AND MCMAHON, F. G. Efficacy and acceptability of different dosage schedules of clonidine, 382
—. (*See* McMahon et al.), 272
—. (*See* Ryan et al.), 231
JERINA, D. M. (*See* Kapitulnik et al.), 158
JONEN, H. G. (*See* Meinertz et al.), 731
JONES, N. L. (*See* Sutton et al.), 700
JONES, R. T. (*See* Benowitz and Jones), 336
JONKMAN, J. H. G., VAN BORK, L. E., WIJSBEEK, J., DE ZEEUW, R. A., AND ORIE, N. G. M. Variations in the bioavailability of thiazinamium methylsulfate, 457
JORFELDT, L. (*See* Frisk-Holmberg et al.), 675
JOYCE, T. H. (*See* Greenblatt et al.), 222
JUHLIN-DANNFELDT, A. (*See* Frisk-Holmberg et al.), 675
JUSTICE, G. R. (*See* Corder et al.), 464

K

KADAR, D. (*See* Kalow et al.), 530
KALOW, W., KADAR, K., INABA, T., AND TANG, B. K. A case of deficiency of N-hydroxylation of amobarbital, 530
KANE, R. E. (*See* Lang et al.), 234
KAPITULNIK, J., LEVIN, W., LU, A. Y. H., MORECKI, R., DANSETTE, P. M., JERINA, D. M., AND CONNEY, A. H. Hydration of arene and alkene oxides by epoxide hydrase in human liver microsomes, 158
—, POPPERS, P. J., AND CONNEY, A. H. Comparative metabolism of benzo[a]pyrene and drugs in human liver, 166
KAPLANSKI, J. (*See* Danon et al.), 643
KARCH, F. E., AND LASAGNA, L. Toward the operational identification of adverse drug reactions, 247
KATZ, F. H., AND HOEHN, M. M. Effects of levodopa on the renin-aldosterone system, 388
KAUFMANN, J. S. (*See* Davis et al.), 52
KENNEDY, W. F. (*See* Wong et al.), 709
KERSTING, F., REID, J. L., AND DOLLERY, C. T. Clinical and cardiovascular effects of alpha methyldopa in combination with decarboxylase inhibitors, 547
KESTENBAUM, R. S. (*See* Resnick et al.), 409
KLOTZ, U., AND ANTONIN, K. H. Pharmacokinetics and bioavailability of sodium valproate, 736
—, —, BRÜGEL, H., AND BIECK, P. R. Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease, 430
KNOWLES, J. A. (*See* Greenblatt et al.), 222
KRAKOFF, L. R. (*See* Vlachakis et al.), 9
KULKARNI, R. D., DASILVA, L. M., CHABRIA, N. L., AND CHADHA, D. R. Beta-2 adrenoceptor blocking activity of penbutolol and propranolol at very low doses, 685
KUMAR, R., COOKE, E. C., LADER, M. H., AND RUSSELL, M. A. H. Is nicotine important in tobacco smoking? 520
KUSHNER, W. (*See* Atkinson et al.), 575
KWAN, K. C. (*See* Duggan et al.), 326
KYRIAKOPOULOS, A. A. (*See* Greenblatt et al.), 222

L

LADER, M. (*See* Nikitopoulou et al.), 422
LADER, M. H. (*See* Kumar et al.), 520
LAKE, C. R. (*See* de la Vega et al.), 216
LALKA, D. (*See* Ludden et al.), 287
LAMPMAN, T. (*See* Yacobi et al.), 283
LANG, G. R., WESTENFELDER, C., NASCIMENTO, L., DHUPELIA, V. B., ARRUDA, J. A. L., AND KANE, R. E. Metolazone and spironolactone in cirrhosis and the nephrotic syndrome, 234
LANGONE, J. J. (*See* Bachur et al.), 70
LASAGNA, L. Dose-related sleep disturbances induced by coffee and caffeine, 244 (Correspondence)
—. (*See* Calimlim et al.), 34
—. (*See* Hassar et al.), 515
—. (*See* Karch and Lasagna), 247
LAU, D. H. M. (*See* Henderson et al.), 16
LEE, W.-K. (*See* Atkinson et al.), 575
LEGER, R. M. (*See* Olsen et al.), 147
LEI, B. W. (*See* Duggan et al.), 326
LEUNG, F. W. (*See* Malcolm et al.), 567
LEVIN, W. (*See* Kapitulnik et al.), 158
LEVINE, L. (*See* Bachur et al.), 70
—. (*See* Øie and Levy), 627
—. (*See* Yacobi et al.), 283
LI, C. (*See* Luders et al.), 721
LIJNEN, P. (*See* Amery et al.), 691
LINDENBAUM, J. Greater bioavailability of digoxin solution in capsules, 278
LIVERMORE, J. D. (*See* Olsen et al.), 147
LU, A. Y. H. (*See* Kapitulnik et al.), 158
LUDDEN, T. M., ALLEN, J. P., VALUTSKY, W. A., VICUNA, A. V., NAPPI, J. M., HOFFMAN, S. F., WALLACE, J. E., LALKA D., AND MCNAY, J. L. Individualization of phenytoin dosage regimens, 287
LUDERS, R. C., MAGGIO-CAVALIERE, M. B., EGGER, H., GUM, O. B., RESNICK, O., BARTLETT, M. F., GAITO, M. J., SOO, A., AND LI, C. Disposition of pirprofen, a new anti-inflammatory drug, 721
LYNN, R. K. (*See* Olsen et al.), 147

M

MACLAUGHLIN, D. S. (*See* Greenblatt et al.), 222
MAGGIO-CAVALIERE, M. B. (*See* Luders et al.), 721

MAGRINAT, G. (*See* Perez et al.), 449
MAGUIRE, K. P. (*See* Norman et al.), 453
MALCOLM, A. D., LEUNG, F. Y., FUCHS, J. C. A., AND DUARTE, J. E. Digoxin kinetics during furosemide administration, 567
MÄNNISTÖ, P. Absorption of rifampin from various preparations and pharmaceutic forms, 370
MARPOLE, D. G. F. (*See* Sniderman et al.), 267
MARTIN, W. E. (*See* Wong et al.), 709
MARTINEZ-MALDONADO, M. (*See* Thompson et al.), 392
MATHIAS, C. J. (*See* Reid et al.), 375
MCAINSH, J. (*See* Amery et al.), 691
MCDEVITT, D. G., BROWN, H. C., CARRUTHERS, S. G., AND SHANKS, R. G. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade, 556
MCDONALD, R. (*See* Sutton et al.), 700
MCGUIRE, E. A. (*See* Vestal et al.), 343
MCMAHON, F. G., RYAN, J. R., JAIN, A. K., VARGAS, R., AND VANOV, S. K. Guanabenz in essential hypertension, 272
—. (*See* Jain et al.), 382
—. (*See* Ryan et al.), 231
MCNAY, J. L. (*See* Ludden et al.), 287
MEFFIN, P. J. (*See* Williams et al.), 301
MEINERTZ, T., GILFRICH, H.-J., GROTH, U., JONEN, H. G., AND JÄHNCHEN, E. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine, 731
MELMON, K. L. (*See* Williams et al.), 301
MENDLOWITZ, M. (*See* Vlachakis et al.), 9
MEZEY, E. (*See* Vestal et al.), 343
MITCHELL, J. (*See* Bloomfield et al.), 414
MORECKI, R. (*See* Kapitulnik et al.), 158
MURPHY, D. L. (*See* de la Vega et al.), 216

N

NAPPI, J. M. (*See* Ludden et al.), 287
NASCIMENTO, L. (*See* Lang et al.), 234
NEESE, A. L., AND SOYKA, L. F. Development of a radioimmunoassay for theophylline, 633
NEILL, E. (*See* Davies et al.), 593
—. (*See* Reid et al.), 375
NELSON, D. (*See* Hassar et al.), 515
NEVIN, M. J. (*See* Atkinson et al.), 575
NIES, A. S. (*See* Walter and Nies), 706
NIKITOPOULOU, G., THORNER, M., CRAMMER, J., AND LADER, M. Prolactin and psychophysiologic measures after single doses of thioridazine, 422
NOEL, B. J. (*See* Greenblatt et al.), 497 (Special article)
NORMAN, T. R., BURROWS, G. D., MAGUIRE, K. P., RUBINSTEIN, G., SCOGGINS, B. A., AND DAVIES, B. Cigarette smoking and plasma nortriptyline levels, 453
NORRIS, A. H. (*See* Vestal et al.), 343

O

OGILVIE, R. I. (*See* Piafsky et al.), 310
ØIE, S., AND LEVY, G. Interindividual differences in the effect of drugs on bilirubin plasma binding in newborn infants and in adults, 627
OLSEN, G. D., WENDEL, H. A., LIVERMORE, J. D., LEGER, R. M., LYNN, R. K., AND GERBER, N. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers, 147
O'MALLEY, K. (*See* Rose et al.), 141
OPELZ, G. (*See* Rachelefsky and Opelz), 44
ORIE, N. G. M. (*See* Jonkman et al.), 457
OSTER, J. R. (*See* Perez et al.), 449

P

PEREZ, G. O., OSTER, J. R., MAGRINAT, G., AND VAAMONDE, C. A. Effect of long-term lithium administration on renal phosphorus handling, 449
PETIT, J. M., SPIKER, D. G., RUWITCH, J. F., ZIEGLER, V. E., WEISS, A. N., AND BIGGS, J. T. Tricyclic antidepressant plasma levels and adverse effects after overdose, 47
PIAFSKY, K. M., SITAR, D. S., RANGNO, R. E., AND OGILVIE, R. I. Theophylline kinetics in acute pulmonary edema, 310
POCELINKO, R. (*See* Hassar et al.), 515
POOLE, D. (*See* Resnick et al.), 409
POPPERS, P. J. (*See* Kapitulnik et al.), 166
POWLES, P. (*See* Sutton et al.), 700
PRUITT, A. W., WINKEL, J. S., AND DAYTON, P. G. Variations in the fate of triamterene, 610
—. (*See* Rose et al.), 141

Q

QUINN, M. L. (*See* Atkinson et al.), 575

R

RACHELEFSKY, G. S., AND OPELZ, G. Normal lymphocyte function in the presence of delta-9-tetrahydrocannabinol, 44
RAFT, D., GREGG, J., GHIA, J., AND HARRIS, L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain, 26
RAMSAY, L., ASBURY, M., SHELTON, J., AND HARRISON, I. Spironolactone and canrenoate-K: Relative potency at steady state, 602
RANE, A. (*See* Hoppel et al.), 294
RANGNO, R. E. (*See* Piafsky et al.), 310
REID, J. L., WING, L. M. H., MATHIAS, C. J., FRANKEL, H. L., AND NEILL, E. The central hypotensive effect of clonidine, 375
—. (*See* Davies et al.), 593
—. (*See* Kersting et al.), 547
RESNICK, O. (*See* Luders et al.), 721

RESNICK, R. B., KESTENBAUM, R. S., WASHTON, A., AND POOLE, D. Naloxone-precipitated withdrawal: A method for rapid induction into naltrexone, 409
REYBROUCK, T. (*See* Amery et al.), 691
RICHTER, E. (*See* Breimer et al.), 470
RIGGS, C. E., JR. (*See* Bachur et al.), 70
RINGBERGER, V.-A. (*See* Åsberg et al.), 201
—. (*See* Siwers et al.), 194
ROBINSON, P. R. (*See* Baty and Robinson), 177
ROSE, H. J., O'MALLEY, K., AND PRUITT, A. W. Depression of renal clearance of furosemide in man by azotemia, 141
ROSENFELD, J. B. (*See* Traub and Rosenfeld), 588
ROVNER, D. R. (*See* Ferguson et al.), 62
ROWLAND, M. (*See* Williams et al.), 301
RUBINSTEIN, G. (*See* Norman et al.), 453
RUCHTE, I. R. (*See* Davis et al.), 52
RUELIUS, H. W. (*See* Greenblatt et al.), 222
RUSSELL, M. A. H. (*See* Kumar et al.), 520
RUWITCH, J. F. (*See* Petit et al.), 47
RYAN, J. R., JAIN, A. K., MCMAHON, F. G., AND VARGAS, R. On the question of an interaction between sulindac and tolbutamide in the control of diabetes, 231
—. (*See* Jain et al.), 382
—. (*See* McMahon et al.), 272

S

SAWCHUK, R. J., ZASKE, D. E., CIPOLLE, R. J., WARGIN, W. A., AND STRATE, R. G. Kinetic model for gentamicin dosing with the use of individual patient parameters, 362
SCHROGIE, J. J., HENSLEY, M. J., DIGIORE, C., AND HARRIS, S. Evaluation of the prison inmate as a subject in drug assessment, 1
SCOGGINS, B. A. (*See* Norman et al.), 453
SCOTT, R. B., TISDALE, S. A., JR., AND CUMMINGS, W. B. Hemolytic potential of methocarbamol, 208
SHADER, R. I. (*See* Greenblatt et al.), 222, 355, 497 (Special article)
SHANKS, R. G. (*See* McDevitt et al.), 556
SHAW, C. L. (*See* Wong et al.), 709
SHEETS, R. F. (*See* Corder et al.), 464
SHELTON, J. (*See* Ramsay et al.), 602
SHERRARD, D. J. (*See* Goldberg et al.), 317
SHIMIZU, M., AND SMITH, D. F. Salivary and urinary lithium clearance while recumbent and upright, 212
SITAR, D. S. (*See* Piafsky et al.), 310
SIWERS, B., RINGBERGER, V.-A., TUCK, J. R., AND SJÖQVIST, F. Initial clinical trial based on biochemical methodology of zimelidine (a serotonin uptake inhibitor) in depressed patients, 194
SJÖQVIST, F. (*See* Åsberg et al.), 201
—. (*See* Hoppel et al.), 294
—. (*See* Siwers et al.), 194
SLATER, S. (*See* de la Vega et al.), 216
SMITH, D. F. (*See* Shimizu and Smith), 212
SNIDERMAN, A. D., MARPOLE, D. G. F., AND FALLEN, E. L. Differences between the effects of practolol and propranolol on the diastolic properties of the left ventricle, 267
SOO, A. (*See* Luders et al.), 721
SOYKA, L. F. (*See* Neese and Soyka), 633
SPIKER, D. G. (*See* Petit et al.), 47
STONE, W. H. (*See* Corder et al.), 464
STORSTEIN, L. Studies on digitalis. VIII. Digitoxin metabolism on maintenance regimen and after a single dose, 125
—, AND AMLIE, J. Studies on digitalis. IX. Some kinetic aspects of digitoxin metabolism, 255
—. Studies on digitalis. X. Digitoxin metabolites in human myocardium and relationship between myocardial and serum concentrations of digitoxin in patients on maintenance treatment, 395
—. Studies on digitalis. XI. Digitoxin metabolism in patients with impaired renal function, 536
—, AND AMLIE, J. Studies on digitalis. XII. Kinetic pattern of digitoxin metabolism in patients with biliary fistulas, 659
STRANDJORD, R. E. (*See* Dahl and Strandjord), 437
STRATE, R. G. (*See* Sawchuk et al.), 362
STRONG, J. M. (*See* Atkinson et al.), 575
SUTTON, J. R., HUGHSON, R. L., MCDONALD, R., POWLES, P., JONES, N. L., AND FITZGERALD, J. D. Oral and intravenous propranolol during exercise, 700

T

TALSETH, T. Kinetics of hydralazine elimination, 715
TANG, B. K. (*See* Kalow et al.), 530
THOMAS, G. (*See* Hassar et al.), 515
THOMAS, R. (*See* Aldous and Thomas), 647
THOMPSON, E. J., TORRES, E., GROSBERG, S. J., AND MARTINEZ-MALDONADO, M. Effect of triamterene on potassium excretion in cirrhotic patients receiving furosemide, 392
THORÉN, P. (*See* Åsberg et al.), 201
THORNÉR, M. (*See* Nikitopoulou et al.), 422
TIPPETT, P. (*See* Davies et al.), 593
TISDALE, S. A., JR. (*See* Scott et al.), 208
TOBIN, J. D. (*See* Vestal et al.), 343
TORRES, E. (*See* Thompson et al.), 392
TRÄSKMAN, L. (*See* Åsberg et al.), 201
TRAUB, Y. M., AND ROSENFELD, J. B. Once-a-day pindolol in hypertension, 588
TUCK, J. R. (*See* Åsberg et al.), 201
—. (*See* Siwers et al.), 194
TUREK, D. M. (*See* Ferguson et al.), 62
TURNER, R. A. (*See* Davis et al.), 52

V

VAAMONDE, C. A. (*See* Perez et al.), 449
VALUTSKY, W. A. (*See* Ludden et al.), 287
VAN BORK, L. E. (*See* Jonkman et al.), 457
VAN DER KLEIJN, E. (*See* van Prooijen et al.), 744
VAN PROOIJEN, R., VAN DER KLEIJN, E., AND HAANEN, C. Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia, 744
VAN VUNAKIS, H. (*See* Bachur et al.), 70
VANOV, S. K. (*See* McMahon et al.), 272
VARGAS, R. (*See* Jain et al.), 382
—. (*See* McMahon et al.), 272
—. (*See* Ryan et al.), 231
VESELL, E. S. (*See* Hepner and Vesell), 620
VESTAL, R. E., MCGUIRE, E. A., TOBIN, J. D., ANDRES, R., NORRIS, A. H., AND MEZEY, E. Aging and ethanol metabolism, 343
VICUNA, A. V. (*See* Ludden et al.), 287
VLACHAKIS, N. D., MENDLOWITZ, M., AND KRAKOFF, L. R. Antihypertensive effects of tolamolol, 9

W

WALLACE, J. E. (*See* Ludden et al.), 287
WALTER, I. E., AND NIES, A. S. Safety of single large oral doses of guanethidine, 706
WARDELL, W. M. (*See* Calimlim et al.), 34
WARGIN, W. A. (*See* Sawchuk et al.), 362
WASHTON, A. (*See* Resnick et al.), 409
WEINTRAUB, M. (*See* Hassar et al.), 515
WEISS, A. N. (*See* Petit et al.), 47
WENDEL, H. A. (*See* Olsen et al.), 147
WESTENFELDER, C. (*See* Lang et al.), 234
WIJSBEEK, J. (*See* Jonkman et al.), 457
WILLIAMS, R. L., BLASCHKE, T. F., MEFFIN, P. J., MELMON, K. L., AND ROWLAND, M. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide, 301
WILSON, B. K. (*See* Henderson et al.), 16
WING, L. M. H. (*See* Davies st al.), 593
—. (*See* Reid et al.), 375
WINKEL, J. S. (*See* Pruitt et al.), 610
WONG, K. C., MARTIN, W. E., KENNEDY, W. F., AKAMATSU, T. J., CONVERY, R. F., AND SHAW, C. L. Cardiovascular effects of total hip placement in man, 709

Y

YACOBI, A., LAMPMAN, T., AND LEVY, G. Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults, 283

Z

ZASKE, D. E. (*See* Sawchuk et al.), 362
ZIEGLER, M. G. (*See* de la Vega et al.), 216
ZIEGLER, V. E. (*See* Petit et al.), 47
ZILLY, W. (*See* Breimer et al.), 470

Subject index

A

Absorption and metabolism of lanatoside C (Aldous and Thomas), 647
Acetaminophen production in man after coadministration of acetanilid and phenacetin (Baty and Robinson), 177
Acetanilid and phenacetin, acetaminophen production in man after coadministration of (Baty and Robinson), 177
Acetylprocainamide, N-, dose-ranging trial of, in patients with premature ventricular contractions (Atkinson et al.), 575
Adrenoceptor blockade, beta, influence of intrinsic sympathomimetic activity and cardioselectivity on (McDevitt et al.), 556
  blocking activity, beta-2, of penbutolol and propranolol at very low doses (Kulkarni et al.), 685
Adriamycin, plasma, and daunorubicin levels by fluorescence and radioimmunoassay (Bachur et al.), 70
Adults, interindividual differences in effect of drugs on bilirubin plasma binding in newborn infants and (Øie and Levy), 627
Age-related changes in body composition important factors in study of ethanol metabolism (Vestal et al.), 343
Aging and ethanol metabolism (Vestal et al.), 343
Aldosterone system, renin-, effects of levodopa on (Katz et al.), 388
Alkene oxides, arene and, hydration of, by epoxide hydrase in human liver microsomes (Kapitulnik et al.), 158
Alprenolol, influence of, on hemodynamic and metabolic responses to prolonged exercise in subjects with hypertension (Frisk-Holmberg et al.), 675
American Society for Clinical Pharmacology and Therapeutics, announcement, 245
  message from President, 245
  notes of, 751
  Seventy-eighth Annual Meeting, abstracts of papers, 97
  Seventy-eighth Annual Meeting, meeting program, 89
Aminopyrine metabolism in presence of hyperbilirubinemia due to cholestasis or hepatocellular disease (Hepner and Vesell), 620
Amobarbital, case of deficiency of N-hydroxylation of (Kalow et al.), 530
Analgesic efficacy of orally administered combination of pentazocine and aspirin (Calimlim et al.), 34
Antipyrine, hexobarbital and, differences between; influence of rifampicin on drug metabolism (Breimer et al.), 470
Arene and alkene oxides, hydration of, by epoxide hydrase in human liver microsomes (Kapitulnik et al.), 158
Arthritis, rheumatoid, fenoprofen, aspirin, and gold induction in (Davis et al.), 52
Aspirin, fenoprofen, and gold induction in rheumatoid arthritis (Davis et al.), 52
  naproxen, and codeine in postpartum uterine pain (Bloomfield et al.), 414
  pentazocine and, analgesic efficacy of orally administered combination of (Calimlim et al.), 34
Atenolol and pharmacologic effect, relationship between blood level of atenolol and (Amery et al.), 691
Atropine, propranolol and, intrinsic sinoatrial frequency at rest and during exercise measured after administration of (Sutton et al.), 700
Azotemia, depression of renal clearance of furosemide in man by (Rose et al.), 141

B

Barbiturates, central nervous system depression together with ingestion of benzodiazepines (Greenblatt et al.), 497 (Special article)
Bayes, haze of, aerial palaces of decision analysis, and computerized Ouija board (Feinstein), 482 (Clinical biostatistics)
Benzo[a]pyrene and drugs in human liver, comparative metabolism of (Kapitulnik et al.), 166
Benzodiazepine derivatives, acute overdosage with (Greenblatt et al.), 497 (Special article)
Beta adrenoceptor blockade, influence of intrinsic sympathomimetic activity and cardioselectivity on (McDevitt et al.), 556
Beta-2 adrenoceptor blocking activity of penbutolol and propranolol at very low doses (Kulkarni et al.), 685
Biliary fistulas, kinetic pattern of digitoxin metabolsim in patients with (Storstein and Amlie), 659
Bilirubin plasma binding in newborn infants and in adults, interindividual differences in effect of drugs on (Øie and Levy), 627
Bioavailability, decreased, of chlorpromazine due to presystemic metabolism (Dahl and Strandjord), 437
  greater, of digoxin solution in capsules (Lindenbaum), 278

January, pp. 1-124; February, pp. 125-246; March, pp. 247-374; April, pp. 375-514; May, pp. 515-642; June, pp. 643-768.

Bioavailability—cont'd
pharmacokinetics and, of sodium valproate (Klotz and Antonin), 736
of thiazinamium methylsulfate, variations in (Jonkman et al.), 457
unannounced change by manufacturer affecting outbreak of digoxin intoxication (Danon et al.), 643
Biostatistics, clinical (Feinstein)
XXXVIII. Computer malpractice, 78
XXXIX. The haze of Bayes, the aerial palaces of decision analysis, and the computerized Ouija board (Feinstein), 482
Blood level of atenolol and pharmacologic effect, relationship between (Amery et al.), 691
pressure control, better from clonidine administered 3 times a day than once daily (Jain et al.), 382
falls in, related to plasma concentration in administration of intravenous and oral clonidine (Davies et al.), 593
response to once-a-day pindolol in hypertension (Traub and Rosenfeld), 588
Books received, 124, 246, 642
Brain, direct action on hypotensive effect of clonidine in man due to (Reid et al.), 375
Breast cancer, leucovorin in combination chemotherapy of (Corder et al.), 464

C

Caffeine, coffee and, dose-related sleep disturbances induced by, 244 (Correspondence)
Cancer, breast, leucovorin in combination chemotherapy of (Corder et al.), 464
Canrenoate-K, spironolactone and; relative potency at steady state (Ramsay et al.), 602
Cardioselectivity, influence of intrinsic sympathomimetic activity and, on beta adrenoceptor blockade (McDevitt et al.), 556
Cardiovascular effects assessed in hypertensive patients after administration of guanethidine (Walter and Nies), 706
clinical and, of alpha methyldopa in combination with decarboxylase inhibitors (Kersting et al.), 547
of total hip placement in man (Wong et al.), 709
responses to intravenous isoproterenol, phenylephrine, atropine, and propranolol compared to evaluate effects of THC on autonomic nervous system function (Benowitz and Jones), 336
Central nervous system depression in benzodiazepine overdosage (Greenblatt et al.), 497 (Special article)
Cerebrospinal fluid, monoamine metabolites in, and serotonin uptake inhibition during treatment with chlorimipramine (Åsberg et al.), 201
Chemotherapy, combination, of breast cancer, leucovorin in (Corder et al.), 464
Chlorimipramine, monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with (Åsberg et al.), 201
Chlorpromazine, pharmacokinetics of, after single and chronic dosage (Dahl and Strandjord), 437
Cholestasis or hepatocellular disease, aminopyrine metabolism in presence of hyperbilirubinemia due to (Hepner and Vesell), 620
Cholestyramine, interruption of enterohepatic circulation of phenprocoumon by (Meinertz et al.), 731
Cigarette smoking and plasma nortriptyline levels (Norman et al.), 453
Cirrhosis and nephrotic syndrome, metolazone and spironolactone in (Lang et al.), 234
Cirrhotic patients receiving furosemide, effect of triamterene on potassium excretion in (Thompson et al.), 392
Clinical biostatistics (Feinstein)
XXXVIII. Computer malpractice, 78
XXXIX. The haze of Bayes, the aerial palaces of decision analysis, and the computerized Ouija board (Feinstein), 482
Clinical and cardiovascular effects of alpha methyldopa in combination with decarboxylase inhibitors (Kersting et al.), 547
pharmacokinetics of lorazepam, intramuscular injection (Greenblatt et al.), 222
Pharmacology and Therapeutics, American Society for, announcement, 245
message from President, 245
notes of, 751
Seventy-eighth Annual Meeting, abstracts of papers, 97
Seventy-eighth Annual Meeting, meeting program, 89
Clofibrate toxicity, control of, in uremic hypertriglyceridemia (Goldberg et al.), 317
Clonidine, central hypotensive effect of (Reid et al.), 375
efficacy and acceptability of different dosage schedules of (Jain et al.), 382
intravenous and oral, pharmacokinetics and concentration-effect relationships of (Davies et al.), 593
Codeine, naproxen, and aspirin in postpartum uterine pain (Bloomfield et al.), 414
Coffee and caffeine, dose-related sleep disturbances induced by, 244 (Correspondence)
Computer malpractice (Feinstein), 78 (Clinical biostatistics)
Cytosine arabinoside in acute myeloid leukemia, pharmacokinetics of (van Prooijen et al.), 744

D

Dalmane (flurazepam) therapy of insomnia, potential hazards of (Greenblatt et al.), 355
Daunorubicin levels, plasma adriamycin and, by fluorescence and radioimmunoassay (Bachur et al.), 70
Decarboxylase inhibitors, clinical and cardiovascular effects of alpha methyldopa in combination with (Kersting et al.), 547
Depressed patients, initial clinical trial based on biochemical methodology of zimelidine (serotonin uptake inhibitor), in (Siwers et al.), 194
Desmethyldiazepam, major metabolite of diazepam, disposition of, in patients with liver disease (Klotz et al.), 430
Diabetes, question of interaction between sulindac and tolbutamide in control of (Ryan et al.), 231
Diastolic properties of left ventricle, differences between effects of practolol and propranolol on (Sniderman et al.), 267
Diazepam, intravenous, and placebo, tetrahydrocannabinol compared to, as premedication for dental extraction (Raft et al.), 26
  and its major metabolite desmethyldiazepam in patients with liver disease, disposition of (Klotz et al.), 430
  overdosage increase relative to other psychotropic drugs (Greenblatt et al.), 497 (Special article)
Digitalis, studies on, digitoxin metabolism on maintenance regimen and after single dose (Storstein), 125
    in patients with impaired renal function (Storstein), 536
    metabolites in human myocardium and relationship between myocardial and serum concentrations of digitoxin in patients on maintenance treatment (Storstein), 395
  kinetic pattern of digitoxin metabolism in patients with biliary fistulas (Storstein and Amlie), 659
  some kinetic aspects of digitoxin metabolism (Storstein and Amlie), 255
Digitoxin metabolism, kinetic pattern of, in patients with biliary fistulas (Storstein and Amlie), 659
  on maintenance regimen and after single dose (Storstein), 125
  in patients with impaired renal function (Storstein), 536
  some kinetic aspects of, studies on digitalis (Storstein and Amlie), 255
metabolites in human myocardium and relationship between myocardial and serum concentrations of digitoxin in patients on maintenance treatment (Storstein), 395
Digoxin intoxication, outbreak of (Danon et al.), 643
  kinetics during furosemide administration (Malcolm et al.), 567
  solution, greater bioavailability of, in capsules (Lindenbaum), 278
Dinoracetylmethadol, plasma elimination curves for, after acute and chronic administration (Henderson et al.), 16
Disease-induced alterations in drug disposition, combined use of laboratory tests to study (Hepner and Vesell), 620
Disease, liver, disposition of diazepam and its major metabolite desmethyldiazepam in patients with (Klotz et al.), 430
Diuretic, triamterene, pteridine used therapeutically as (Pruitt et al.), 610
Dopamine beta-hydroxylase activity, reduction in, during fenfluramine treatment (de la Vega et al.), 216
Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions (Atkinson et al.), 575
Drug(s), anti-inflammatory, therapeutic advantages relating to gastrointestinal intolerance usually associated with (Duggan et al.), 326
  assessment, evaluation of prison inmate as subject in (Schrogie et al.), 1
  benzo[a]pyrene and, in human liver, comparative metabolism of (Kapitulnik et al.), 166
  interindividual differences in effect of, on bilirubin plasma binding in newborn infants and in adults (Øie and Levy), 627
  metabolism, influence of rifampicin on; differences between hexobarbital and antipyrine (Breimer et al.), 470
  pirprofen new anti-inflammatory, disposition of (Luders et al.), 721
  reactions, adverse, operational identification of (Karch and Lasagna), 247

E

Edema, acute pulmonary, theophylline kinetics in (Piafsky et al.), 310
Enterohepatic circulation of phenprocoumon by cholestyramine, interruption of (Meinertz et al.), 731
Epoxide hydrase, hydration of arene and alkene oxides by, in human liver microsomes (Kapitulnik et al.), 158
Ethanol metabolism, aging and (Vestal et al.), 343
Exercise, oral and intravenous propranolol during (Sutton et al.), 700
  prolonged, influence of alprenolol on hemodynamic and metabolic responses to, in subjects with hypertension (Frisk-Holmberg et al.), 675

F

Fenfluramine treatment, reduction in plasma norepinephrine during (de la Vega et al.), 216

Fenoprofen, aspirin, and gold induction in rheumatoid arthritis (Davis et al.), 52
Fistulas, biliary, kinetic pattern of digoxin metabolism in patients with (Storstein and Amlie), 659
Fludrocortisone mineralocorticoid agonist in defining relative dose ratios of spironolactone and canrenoate-K (Ramsay et al.), 602
Fluorescence and radioimmunoassay, plasma adriamycin and daunorubicin levels by (Bachur et al.), 70
Flurazepam, high-dose, toxicity of, in elderly (Greenblatt et al.), 355
Furosemide administration, digoxin kinetics during (Malcolm et al.), 567
  depression of renal clearance of, in man by azotemia (Rose et al.), 141
  effect of triamterene on potassium excretion in cirrhotic patients receiving (Thompson et al.), 392

G

Gentamicin dosing, kinetic model for, with use of individual patient parameters (Sawchuk et al.), 362
GLOBAL subjective efficacy ratings in study of analgesic efficacy of orally administered combination of pentazocine and aspirin (Calimlim et al.), 34
Gold induction, fenoprofen, aspirin, and, in rheumatoid arthritis (Davis et al.), 52
Guanabenz in essential hypertension (McMahon et al.), 272
Guanethidine, safety of single large oral doses of (Walter and Nies), 706

H

Heart failure, great variability in plasma clearance of theophylline in patients with (Piafsky et al.), 310
  rabbit, observations on effects of methylmethacrylate on (Wong et al.), 709
  rates after parasympathetic and combined parasympathetic and sympathetic blockade during THC ingestion (Benowitz and Jones), 336
Hemodynamic and metabolic responses to prolonged exercise in subjects with hypertension, influence of alprenolol on (Frisk-Holmberg et al.), 675
Hemolytic potential of methocarbamol (Scott et al.), 208
Hepatitis, acute viral, influence of, on disposition and plasma binding of tolbutamide (Williams et al.), 301
Hepatocellular disease, cholestasis or, aminopyrine metabolism in presence of hyperbilirubinemia due to (Hepner and Vesell), 620
Hexobarbital and antipyrine, differences between; influence of rifampicin on drug metabolism (Breimer et al.), 470
Hip placement in man, cardiovascular effects of (Wong et al.), 709
Hydralazine elimination, kinetics of (Talseth), 715
Hydrochlorothiazide, spironolactone and, in normal-renin and low-renin essential hypertension (Ferguson et al.), 62
Hydroxylation, N-, of amobarbital, case of deficiency of (Kalow et al.), 530
Hyperbilirubinemia, aminopyrine metabolism in presence of, due to cholestasis or hepatocellular disease (Hepner and Vesell), 620
Hypertension, dosage schedules with clonidine tailored to individual cases of (Jain et al.), 382
  essential, guanabenz in (McMahon et al.), 272
  influence of alprenolol on hemodynamic and metabolic responses to prolonged exercise in subjects with (Frisk-Holmberg et al.), 675
  mild to moderately severe, guanabenz effective antihypertensive drug in patients with (McMahon et al.), 272
  normal-renin and low-renin essential, spironolactone and hydrochlorothiazide in (Ferguson et al.), 62
  once-a-day pindolol in (Traub and Rosenfeld), 588
Hypertensive, anti-, effects of tolamolol (Vlachakis et al.), 9
  patients, cardiovascular effects assessed after administration of guanethidine (Walter and Nies), 706
    treated with atenolol in weekly increasing doses, relationship between blood level of atenolol and pharmacologic effect (Amery et al.), 691
Hypertriglyceridemia, uremic, control of clofibrate toxicity in (Goldberg et al.), 317
Hypotensive effect, central, of clonidine (Reid et al.), 375

I

Infants, newborn, and adults, interindividual differences in effect of drugs on bilirubin plasma binding in (Øie and Levy), 627
  premature, application of development of radioimmunoassay for theophylline to studies in (Neese and Soyka), 633
Intoxication, digoxin, outbreak of (Danon et al.), 643

K

Kinetic(s), digoxin, during furosemide administration (Malcolm et al.), 567
  of hydralazine elimination (Talseth), 715

Kinetics—cont'd
model for gentamicin dosing with use of individual patient parameters (Sawchuk et al.), 362
pattern of digitoxin metabolism in patients with biliary fistulas (Storstein and Amlie), 659

L

Laboratory tests, combined use of, to study disease-induced alterations in drug disposition (Hepner and Vesell), 620
Lanatoside C, absorption and metabolism of (Aldous and Thomas), 647
Leucovorin in combination chemotherapy of breast cancer (Corder et al.), 464
Leukemia, acute myeloid, pharmacokinetics of cytosine arabinoside in (van Prooijen et al.), 744
Levodopa, effects of, on renin-aldosterone system (Katz et al.), 388
Lithium administration, long-term, effect of, on renal phosphorus handling (Perez et al.), 449
clearance, salivary and urinary, while recumbent and upright (Shimizu and Smith), 212
Liver disease, disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease (Klotz et al.), 430
human, comparative metabolism of benzo[a]-pyrene and drugs in (Kapitulnik et al.), 166
microsomes, human, hydration of arene and alkene oxides by epoxide hydrase in (Kapitulnik et al.), 158
Lorazepam, clinical pharmacokinetics of; intramuscular injection (Greenblatt et al.), 222
glucuronide, major metabolite of lorazepam, concentrations of determined by electron-capture gas-liquid chromatography (Greenblatt et al.), 222
Lymphocyte function, normal, in presence of delta-9-tetrahydrocannabinol (Rachelefsky and Opelz), 44

M

Malpractice, computer (Feinstein), 78 (Clinical biostatistics)
Man, pharmacologic studies in, free-living volunteer's motivations and attitudes toward (Hassar et al.), 515
Marijuana, delta-9-tetrahydrocannabinol, psychoactive component of, normal lymphocyte function in (Rachelefsky et al.), 44
Mephenesin, methocarbamol, compound related to (Scott et al.), 208
Metabolic responses, hemodynamic and, to prolonged exercise in subjects with hypertension, influence of alprenolol on (Frisk-Holmberg et al.), 675
Metabolism, absorption and, of lanatoside C (Aldous and Thomas), 647
aminopyrine, in presence of hyperbilirubinemia due to cholestasis or hepatocellular disease (Hepner and Vesell), 620
comparative, of benzo[a]pyrene and drugs in human liver (Kapitulnik et al.), 166
digitoxin, kinetic pattern of, in patients with biliary fistulas (Storstein and Amlie), 659
in patients with impaired renal function (Storstein), 536
some kinetic aspects of; studies on digitalis (Storstein and Amlie), 255
drug, influence of rifampicin on; differences between hexobarbital and antipyrine (Breimer et al.), 470
ethanol, aging and (Vestal et al.), 343
overall, of amobarbital in man essentially under genetic control (Kalow et al.), 530
presystemic, decreased bioavailability of chlorpromazine due to (Dahl and Strandjord), 437
Metabolites, digitoxin, in human myocardium and relationship between myocardial and serum concentrations of digitoxin in patients on maintenance treatment (Storstein), 395
monoamine, in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine (Åsberg et al.), 201
Methadone, plasma elimination curves for, after acute and chronic administration (Henderson et al.), 16
racemic, and its optical isomers, clinical effects and pharmacokinetics of (Olsen et al.), 147
Methocarbamol, hemolytic potential of (Scott et al.), 208
Methyldopa, alpha, clinical and cardiovascular effects of, in combination with decarboxylase inhibitors (Kersting et al.), 547
Methylmethacrylate, observations on effects of, on isolated rabbit heart (Wong et al.), 709
Methylsulfate, thiazinamium, variations in bioavailability of (Jonkman et al.), 457
Metolazone and spironolactone in cirrhosis and nephrotic syndrome (Lang et al.), 234
Michaelis-Menten kinetics for DPH metabolism, concept of, in study of plasma concentrations of 4-OH-DPH in phenytoin-treated patients (Hoppel et al.), 294
Miosis, respiratory depression and, induced by *l*-methadone and *d,l*-methadone (Olsen et al.), 147
Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine (Åsberg et al.), 201

Myasthenia gravis, plasma pyridostigmine levels in patients with (Calvey and Chan), 187
Myeloid leukemia, acute, pharmacokinetics of cytosine arabinoside in (van Prooijen et al.), 744
Myocardium, human, digitoxin metabolites in, and relationship between myocardial and serum concentrations of digitoxin in patients on maintenance treatment (Storstein) 395

N

N-acetylprocainamide, dose-ranging trial of, in patients with premature ventricular contractions (Atkinson et al.), 575
Naloxone-precipitated withdrawal; method for rapid induction onto naltrexone (Resnick et al.), 409
Naltrexone, method for rapid induction onto; naloxone-precipitated withdrawal (Resnick et al.), 409
Naproxen, aspirin, and codeine in postpartum uterine pain (Bloomfield et al.), 414
Nephrotic syndrome, cirrhosis and, metolazone and spironolactone in (Lang et al.), 234
Nervous system depression, central, elderly susceptible to at high doses of flurazepam (Greenblatt et al.), 355
function, autonomic, effects of delta-9-tetrahydrocannabinol on (Benowitz and Jones), 336
N-hydroxylation of amobarbital, case of deficiency of (Kalow et al.), 530
Nicotine, is it important in tobacco smoking? (Kumar et al.), 520
Nomogram, use of individual pharmacokinetic parameters compared to, in study of individualization of phenytoin dosage regimens (Ludden et al.), 287
Noracetylmethadol, plasma elimination curves for, after acute and chronic administration (Henderson et al.), 16
Norepinephrine, plasma, reduction in, during fenfluramine treatment (de la Vega et al.), 216
Nortriptyline levels, plasma, cigarette smoking and (Norman et al.), 453

O

Opiate, method for accelerating transition from, to naltrexone (Resnick et al.), 409
Ouija board, computerized, haze of Bayes, aerial palaces of decision analysis, and (Feinstein), 482 (Clinical biostatistics)
Overdosage, acute, with benzodiazepine derivatives (Greenblatt et al.), 497 (Special article)
Oxprenolol, propranolol and, dose-response curves for, studied in healthy volunteers (McDevitt et al.), 556

P

Penbutolol and propranolol at very low doses, beta-2 adrenoceptor blocking activity of (Kulkarni et al.), 685
Pentazocine and aspirin, analgesic efficacy of orally administered combination of (Calimlim et al.), 34
Pharmacokinetic(s) and bioavailability of sodium valproate (Klotz and Antonin), 736
of chlorpromazine after single and chronic dosage (Dahl and Strandjord), 437
clinical effects and, of racemic methadone and its optical isomers (Olsen et al.), 147
of lorazepam; intramuscular injection (Greenblatt et al.), 222
and concentration-effect relationships of intravenous and oral clonidine (Davies et al.), 593
of cytosine arabinoside in acute myeloid leukemia (van Prooijen et al.), 744
parameters, individual, use of, in study of individualization of phenytoin dosage regimens (Ludden et al.), 287
Pharmacologic effect, relationship between blood level of atenolol and (Amery et al.), 691
studies in man, free-living volunteer's motivations and attitudes toward (Hassar et al.), 515
Phenacetin, acetanilid and, acetaminophen production in man after coadministration of (Baty and Robinson), 177
Phenprocoumon, interruption of enterohepatic circulation of, by cholestyramine (Meinertz et al.), 731
Phenytoin dosage regimens, individualization of (Ludden et al.), 287
fraction values in serum of healthy human adults, frequency distribution of free warfarin and (Yacobi et al.), 283
-treated patients, plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin (Hoppel et al.), 294
Phosphorus handling, renal, effect of long-term lithium administration on (Perez et al.), 449
Pindolol, once-a-day, in hypertension (Traub and Rosenfeld), 588
Pirprofen, new anti-inflammatory drug, disposition of (Luders et al.), 721
Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay (Bachur et al.), 70
binding, bilirubin, in newborn infants and in adults, interindividual differences in effect of drugs on (Øie and Levy), 627

Plasma binding—cont'd
of tolbutamide, influence of acute viral hepatitis on disposition and (Williams et al.), 301
concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients (Hoppel et al.), 294
l-α-acetylmethadol (LAAM) after acute and chronic administration (Henderson et al.), 16
levels, tricyclic antidepressant, and adverse effects after overdose (Petit et al.), 47
norepinephrine during fenfluramine treatment, reduction in (de la Vega et al.), 216
nortriptyline levels, cigarette smoking and (Norman et al.), 453
pyridostigmine levels in patients with myasthenia gravis (Calvey and Chan), 187
Potassium excretion, effect of triamterene on, in cirrhotic patients receiving furosemide (Thompson et al.), 392
Practolol and propranolol, differences between effects of, on diastolic properties of left ventricle (Sniderman et al.), 267
Prison inmate, evaluation of, as subject in drug assessment (Schrogie et al.), 1
Procainamide, gastrointestinal side effects and insomnia similar to adverse reactions to N-acetylprocainamide in patients with premature ventricular contractions (Atkinson et al.), 575
Prolactin and psychophysiologic measures after single doses of thioridazine (Nikitopoulou et al.), 422
Propranolol, oral and intravenous, during exercise (Sutton et al.), 700
and oxprenolol, dose-response curves for, studied in healthy volunteers (McDevitt et al.), 556
penbutolol and, at very low doses, beta-2 adrenoceptor blocking activity of (Kulkarni et al.), 685
practolol and, differences between effects of, on diastolic properties of left ventricle (Sniderman et al.), 267
Psychiatric interviews in effects of tetrahydrocannabinol, diazepam, and placebo as premedication for dental extraction (Raft et al.), 26
Psychophysiologic measures, prolactin and, after single doses of thioridazine (Nikitopoulou et al.), 422
Psychotropic drugs, acute overdosage with (Greenblatt et al.), 497 (Special article)
Pteridine, triamterene used therapeutically as diuretic (Pruitt et al.), 610
Public health implications discussed in outbreak of digoxin intoxication (Danon et al.), 643
Pulmonary edema, acute, theophylline kinetics in (Piafsky et al.), 310
Pyridostigmine levels, plasma, in patients with myasthenia gravis (Calvey and Chan), 187

R

Rabbit heart, observations on effects of methylmethacrylate on (Wong et al.), 709
Radioimmunoassay, fluorescence and, plasma adriamycin and daunorubicin levels by (Bachur et al.), 70
for theophylline, development of (Neese and Soyka), 633
Reactions, adverse drug, operational identification of (Karch and Lasagna), 247
Renal clearance of furosemide, depression of, in man by azotemia (Rose et al.), 141
intersubject variation in, of intravenous and oral clonidine (Davies et al.), 593
function, impaired, digitoxin metabolism in patients with (Storstein), 536
phosphorus handling, effect of long-term lithium administration on (Perez et al.), 449
Renin-aldosterone system, effects of levodopa on (Katz et al.), 388
Renin-lowering efficacy and side effects of tolamolol (Vlachakis et al.), 9
Research studies in drug assessment, reasons for exclusion of prisoners from (Schrogie et al.), 1
Respiratory depression and miosis induced by *l*-methadone and *d,l*-methadone (Olsen et al.), 147
Rheumatoid arthritis, fenoprofen, aspirin, and gold induction in (Davis et al.), 52
Rifampicin, influence of, on drug metabolism; differences between hexobarbital and antipyrine (Breimer et al.), 470
Rifampin, absorption of, from various preparations and pharmaceutic forms (Männistö), 370

S

Salivary and urinary lithium clearance while recumbent and upright (Shimizu and Smith), 212
Serotonin uptake inhibition, monoamine metabolites in cerebrospinal fluid and, during treatment with chlorimipramine (Åsberg et al.), 201
inhibitor, zimelidine, initial clinical trial based on biochemical methodology of, in depressed patients (Siwers et al.), 194
Serum concentrations, myocardial and, of digitoxin in patients on maintenance treatment, digitoxin metabolites in human myocardium and relationship between (Storstein), 395

Serum—cont'd
level-time data obtained after single infusion used to determine patient's gentamicin half-life (Sawchuk et al.), 362
protein binding of phenytoin, differences in (Yacobi et al.), 283
rifampin concentrations (Männistö), 370
Sleep disturbances, dose-related, induced by coffee and caffeine, 244 (Correspondence)
Smoking, cigarette, and plasma nortriptyline levels (Norman et al.), 453
tobacco, is nicotine important in? (Kumar et al.), 520
Sodium valproate, pharmacokinetics and bioavailability of (Klotz and Antonin), 736
Spironolactone and canrenoate-K; relative potency at steady state (Ramsay et al.), 602
and hydrochlorothiazide in normal-renin and low-renin essential hypertension (Ferguson et al.), 62
metolazone and, in cirrhosis and nephrotic syndrome (Lang et al.), 234
Sulfide, plasma levels of, following twice daily dosage of sulindac (Duggan et al.), 326
Sulindac, disposition of (Duggan et al.), 326
and tolbutamide, question of interaction between in control of diabetes (Ryan et al.), 231
Surgical pain, experimental and, effects of intravenous tetrahydrocannabinol on (Raft et al.), 26
Sympathomimetic activity, intrinsic, and cardioselectivity, influence of, on beta adrenoceptor blockade (McDevitt et al.), 556

T

Tetraethylammonium, renal clearance of furosemide and, compared in patients with hypertensive nephropathy (Rose et al.), 141
Tetrahydrocannabinol, delta-9-, normal lymphocyte function in presence of (Rachelefsky and Opelz), 44
prolonged ingestion of; effects of sympathomimetic amines and autonomic blockades (Benowitz and Jones), 336
intravenous, effects of, on experimental and surgical pain (Raft et al.) 26
Tetraplegics, data in, hypotensive effect of clonidine in man due to direct action on brain (Reid et al.), 375
Theophylline, development of radioimmunoassay for (Neese and Soyka), 633
kinetics in acute pulmonary edema (Piafsky et al.), 310
Thiazinamium methylsulfate, variations in bioavailability of (Jonkman et al.), 457
Thioridazine, prolactin and psychophysiologic measures after single doses of (Nikitopoulou et al.), 422
Tobacco smoking, is nicotine important in? (Kumar et al.), 520
Tolamolol, antihypertensive effects of (Vlachakis et al.), 9
Tolbutamide, plasma binding of, influence of acute viral hepatitis on disposition and (Williams et al.), 301
sulindac and, question of interaction between, in control of diabetes (Ryan et al.), 231
Toxicity, clofibrate, control of, in uremic hypertriglyceridemia (Goldberg et al.), 317
of high-dose flurazepam in elderly (Greenblatt et al.), 355
Triamterene, effect of, on potassium excretion in cirrhotic patients receiving furosemide (Thompson et al.), 392
variations in fate of (Pruitt et al.), 610
Tricyclic antidepressant plasma levels and adverse effects after overdose (Petit et al.), 47

U

Uremic hypertriglyceridemia, control of clofibrate toxicity in (Goldberg et al.), 317
Urinary lithium clearance, salivary and, while recumbent and upright (Shimizu and Smith), 212
Urine, excretion of rifampin in (Männistö), 370
Uterine pain, naproxen, aspirin, and codeine in (Bloomfield et al.), 414

V

Ventricle, left, differences between effects of practolol and propranolol on diastolic properties of (Sniderman et al.), 267
Ventricular contractions, premature, dose-ranging trial of N-acetylprocainamide in patients with (Atkinson et al.), 575
Viral hepatitis, acute, influence of, on disposition and plasma binding of tolbutamide (Williams et al.), 301
Volunteer's, free-living, motivations and attitudes toward pharmacologic studies in man (Hassar et al.), 515

W

Warfarin, free, and free phenytoin fraction values in serum of healthy human adults, frequency distribution of (Yacobi et al.), 283

Z

Zimelidine (serotonin uptake inhibitor), initial clinical trial based on biochemical methodology of, in depressed patients (Siwers et al.), 194